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Abstract
Background: To evaluate the killing effect of HSV-TK/GCV suicide gene therapy system combined with
60Co
radiotherapy on human cervical cancer Hela cell line in vitro and in vivo, and to explore the radiosensitization by
HSV-TK/GCV system.
Methods: HSV-TK/GCV suicide gene therapy system and
60Co radiotherapy were used separately or in combination
on human cervical cancer Hela cell line in vitro and in vivo to compare their effects. Colony formation test and the
rate of radiosensitization effect (E/O) were employed to observed the radiosensitization by HSV-TK/GCV system.
Results: HSV-TK/GCV suicide gene therapy system had strong therapeutic effects on Hela cells in vitro and in vivo
(the inhibition rates were 45.8% and 39.5%, respectively), moreover, the combined administration of gene therapy
and radiotherapy had stronger therapeutic effects in vitro and in vivo (the inhibition rate was 87.5% in vitro, and
the inhibition rate was 87.9% in vivo) (P < 0.01). The inhibition rate by radiotherapy alone was 42.4% in vitro and
35.8% in vivo. The sensitivity of combined therapy to radiotherapy increased more than that of therapy alone, the
ability of colony formation decreased (P < 0.01). The rate of radiosensitivity effect (E/O) was 3.17(> 1.4), indicating
HSV-TK/GCV system could exert a sensitizing effect on
60Co radiotherapy of the transplanted human cervical cancer
cell in nude mice.
Conclusion: HSV-TK/GCV system had radiosensitization. Gene therapy combined with radiotherapy may be a good
supplementary method for cervix cancer synthetic treatment.
Background
In recent years, molecular mechanism of tumor develop-
ment and cell growth regulating mechanism are further
studied, gene treatment of tumor has made rapid pro-
gress. More attention is paid to HSV-TK/GCV drug
sensitive gene treatment system. But its clinical effect is
not satisfactory, one of the reasons is that effective dose
of GCV (100 mg/kg/1 d) may result in serious toxic side
effect. Main complications are damage to renal function
(40%~60%) and bone marrow inhibition (20%~41%) [1],
which greatly influence and limit application scope and
therapeutic effect of HSV-TK gene treatment. Radio-
therapy is one of the most important clinical means in
the treatment of tumor. Effect of radiotherapy depends
on sensitivity of tumor cells and normal tissue to rays,
but sensitivity is related to radiation dose. Excessive
dose may damage normal tissue adjacent to tumor. So
radiotherapy and gene treatment are both effective
means but they have their own problems.
Tumor development is a complicated process invol-
ving many factors and gene incidents. Treatment of
one link can not achieve satisfactory result. Some
scholars suggested that combination of gene therapy,
radiotherapy, chemotherapy and immunotherapy may
enhance neoplastic suppressing effect. The suicide
gene therapy and radiotherapy interact to produce a
synergistic enhancement of cell kill may make the
combined therapeutic effect even greater [2]. Atkinson
et al [3] gave GCV and combined radiotherapy to
mouse prostate cancer cells with transferred HSV-TK
gene. They found that cell survival rate treated by
simple HSV-TK/GCV system is 10%, 1% for simple
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group. Its effect was not addition, but synergism. Ped-
erson et al [4] used adenoviral as vector, transferred
CD gene to cholecyst cancer cell system SK-chA-1 that
was insensitive to radiation, added 5-FC for culture,
combined with radiotherapy. Tumor cell death rate
with simple 5-FC treatment was 20%~46%, it increased
to 83.5%~91.5% with combined radiotherapy. Animal
experiments also confirmed obvious growth inhibition
of transplanted tumor in nude mice. Research of other
scholars [5] also proved that effect of suicide gene sys-
tem combined with radiotherapy was better than that
of single treatment. Required titre of virus transfected
vector, drug concentration of precursor and radiation
dose were lower than those of single treatment. It
could reduce adverse effect in treatment. So suicide
gene system combined with radiotherapy may be a
prospective scheme.
In present study, the author used reverse transcription
virus to transfer HSV-TK gene into human cervical can-
cer Hela, combined with
60Co radiation to conduct in
vitro and in vivo experiments, and explored its syner-
gism and provided experimental and theoretical basis
for clinical use.
Methods
Cell line and cell culture
Cervical cancer Hela cells were obtained from China
Type Tissure Culture Collection Center (CCTCC,
Wuhan, China); The Hela cells were maintained in
RPMI1640 (Hangzhou Sijiqing Company, China) supple-
mented with 10% FBS in monolayers at 37°C and 5%
CO2. All cells were passaged and harvested by standard
trypsin (Quality Biologicals.Inc.)digestion at 37°C. Cells
were routinely passaged at 80-90% confluence.
vector
GINaTK retroviral vector was kindly provided by Dr.
Daru Lu (Genetic Research Center of Fudan Univercity,
Shanghai, China). The vector is based on the Moloney
murine leukemia virus(MoMLV)long terminal repeat
(LTR) and the cytomegalovirus (CMV) promoter. The
vector included safety modifications to reduce the
chances of retroviral vector recombination leading to
the regeneration of replication-competent virus [6]. The
HSV-TK gene was inserted downstream of the cytome-
galovirus (CMV) promoter in a GINa plasmid contain-
ing NeoR selectable gene, the neomycin resistance gene
encoding for NPT II(neomycin phosphotransferase II),
which protects cells from the toxic effect of G418(a neo-
mycin analog, Promega). NeoR has been used in many
human clinical trials to date without adverse effect.
Construction of package cell PA317/TK has been pre-
viously described [7].
Retroviral transduction of Hela cell line
Supernatant from vector producer cells(PA317/TK)
were obtained from cells that were 90-100% confluent.
This supernatant was filtered through a 0.22 um filter,
then replaced the cell growth medium of Hela by 5 ml
viral supernatant, containing polybrene (8 μg/ml) to
help the adhesion of viruses. Cells were returned to the
incubator for 2 hours, then 5 ml of growth medium was
added and incubated overnight. The next day the super-
natant was removed and the cells were fed. After 2 days
postinfection, we began the selection with 400 μg/ml of
G418 (active drug, GIBCO) in RPMI1640. Cells were
then observed daily and a large fraction of the cells died
between days 4-and 7 of selection. Cells were kept
under 800 μg/ml G418 selection for 14 days. The surviv-
ing HSV-TK-transduced cells(named Hela/TK) were
pooled and used in the subsequent experiments.
Experimental animals
BALB/C nude mice, female, 6-8 weeks old, body weight
about 20 g, were from the Shanghai ExperimentalAni-
mal Center, the Chinese Academy of Sciences (Shang-
hai, China) [licence number:SCXK (Hu) 2002-0010]. All
animal experiments were carried out in compliance with
the national laws related to the conduct of animal
experimentation.
60Co g ray
60Co g ray irradiator (Picker Zonegard V4 M60; Picker
Interational, Cleveland, Ohio), absorptiondose rate was
set at 168.5 cGy/min.
In vitro experiment
Growth inhibition experiment of in vitro cells by HSV-TK
gene combined with
60Co radiation
Hela/TK cells were inoculated in 96-well cell culture
plate (10
3cells/well), and cultured for 24 h, when cells
grew on wall, they were treated as follows: ① gene
treatment group: 10 μg/ml GCV solution was added to
each well; ②
60Co radiotherapy group: each well was
irradiated by
60Co g ray, absorption dose was 400 cGy
③ combined treatment group: 10 μg/ml GCV was
added to each well, and each well was radiated by
60Co
g ray, absorption dose was 400 cGy ④ control group:
no treatment. Each experiment was performed in tripli-
cate. Cells were cultured at 37°C in 5% CO2 incubator
for 4 d, then 10 μl (5 mg/ml) MTT solution was added
to each well of each group, then cultured for 4 h, finally
150 μl DMSO was added to each well, absorbance value
A at 490 nm wavelength was determined, the well with-
out cell was blank, Hela/TK without any treatment was
the control, growth inhibition rate of cells was calcu-
lated with following formula. Inhibition rate (%) was
(absorbance value A of control group minus absorbance
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trol group × 100%
Flow Cytometry Assay
Hela/TK cells were inoculated in 6-well cell culture
plate (5 × 10
3 cells/well), and cultured for 24 h, when
cells grew on wall, they were treated as follows: ① gene
treatment group: 10 μg/ml GCV solution was added to
each well; ②
60Co radiotherapy group: each well was
irradiated by
60Co g ray, absorption dose was 400 cGy
③ Combned treatment group: 10 μg/ml GCV was
added to each well, and each well was radiated by
60Co
g ray, absorption dose was 400 cGy ④ Control group:
no treatment. Each experiment was performed in tripli-
cate. Cells were cultured at 37°C in 5% CO2 incubator
for 2 d. Then the cells of control group and experimen-
tal group were collected and rinsed in 0.1 PBS (pH 7.2
~ 7.4) for three times, resuspended and fixed in 70%
ethanol at 4 overnight. Cells were centrifuged, resus-
pended in 0.1 g/L RNase A at 37°C for 30 min and in
0.05 g/L propidium iodide at 4°C for 30 min. Cell cycle
was analyzed by flow cytometer (FACS Vantage SE, Bec-
ton-Dickson Company).
Radiosensitization of HSV-TK/GCV tested by clone formation
rate of cells
Hela/TK cells were passaged and harvested by standard
trypsin (Quality Biologicals.Inc.)digestion, single cell was
suspending in inoculum. Percentage of single cell was
over 95%, 10
5 cells were inoculated in 6-well plate.
Experiment was divided into 4 groups: ① control group;
② simple agent group (GCV content was 1/10 of effec-
tive concentration, i.e. l μg/ml); ③ simple radiation
group, with certain dose of
60Co radiation, absorption
dose was 400 cGy; ④ combined treatment group, first 1
μg/ml GCV (Cytovene-IV, Roche Laboratories, Nutley,
NJ) was added and then radiated by
60Co, absorption
dose was 400 cGy, which were cultured at 37°C in 5%
CO2 incubator for 14 d, then each well was cleaned
twice with PBS, dried in air, fixed by methanol for 15
min, stained with Giemsa for 15 min, and dye was
washed away with running water, dried again in air,
finally clone was counted more than 50 cells under
microscope, per clone formation rate of cells was calcu-
lated by following formula: clone formation rate of cells
(%) = (clone number/inoculated cell number) × 100%;
relative clone formation rate of cells (%) = (clone forma-
tion rate of radiation group/clone formation rate of con-
trol group) × 100%
In vivo experiment
Establishment of nude mice cervical cancer model and
treatment of tumor
Forty BALB/c nude mice were divided into 4 groups:
control group, gene treatment group,
60Co radiotherapy
group and combined treatment group, 10 mice in each
group. Each nude mouse was injected sc on both sides
of flanks with 3.0 × 10
6 Hela/TK cells. When tumor
grew to 1 cm in diameter, treatment as following: ①
gene treatment group: GCV (100 mg/kg) was given
intra-peritoneal cavity (i.p), injection volume 0.4 ml/
mouse, once one day, continuous injection for 14 d; ②
60Co radiotherapy group: Synchronous with gene treat-
ment group, tumor was radiated with
60Co once,
absorption dose was 20 Gy; ③ combined treatment
group: GCV (100 mg/kg) was given i.p, 2 h later, tumor
tissue radiated with
60Co once, absorption dose was 20
Gy. Other steps were similar to gene treatment group:
④ Control group: same volume of aseptic phosphate
buffer solution was given i.p, but without
60Co radiation.
Four weeks later mice were sacrificed, tumor was
resected and then their weight was weighed respectively
with electro-balance.
Calculating average tumor inhibition rate of each group
Tumor inhibition rate (%) was calculated as (average
tumor weight of control group minus average tumor
weight of experimental group)/average tumor weight of
control group × 100%.
Calculating radiosensitization
Radiosensitization was determined by E/O value
(expected value/observed value) which was reported by
Yunfei Xia et al [8] whether HSV-TK/GCV system had
radiosensitization. When E/O > 1.4, it had radiosensiti-
zation. E = (T2/T1) × (T3/T1), which was expected
value; 0 = (T4/T1), which was observed value. (T1, T2,
T3 and T4 were respectively average tumor weights in
control group, gene treatment group,
60Co radiotherapy
group and combined treatment group).
Analytical and statistical methods
Experimental data were presented as means ± the stan-
dard deviations (SD) of four independent experiments
performed in triplicate. Where appropriate, samples were
analyzed by using the Student’s two-tailed t-test or
ANOVA(analysis of variance) by SPSS software. And sta-
tistical significance was defined as P < 0.05 and P < 0.01.
Results
Results of in vitro experiment
Cell growth inhibition
On 4
th day, inhibition rates of Hela/TK cell growth in
the three treatment group were 45.8 ± 7.3%, 42.4 ± 5.6%
and 87.5 ± 10.32% respectively, compared with gene
treatment group and radiotherapy group, there was a
significant difference in combined treatment group (P <
0.01) (See Figure 1).
Hela/TK cells apoptosis analyzed by FCMs
The percentages of Hela/TK cells apoptosis were ana-
lyzed by FCMs on the fluorescence channel as described
by Zhang [9]. The resulting histogram is a measure of
PI staining, which is indicative of the amount of DNA
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togram of PI staining is a reflection of chromatin con-
tent and the amount of apoptotic cells is in proportion
to the sub-G0/G1-phase. According to the results
shown in Figure 2, the percentages of apoptotic Hela/
TK cells induced by Gene treatment,
60Co radiotherapy
group and combined treatment were 22.76 ± 3.51%,
25.16 ± 3.17%and 45.27 ± 5.15%, respectively, as com-
pared to 0.42 ± 0.13% apoptotic cells in the controls.
Compared with gene treatment group and radiotherapy
group, there was a significant difference in combined
treatment group (P < 0.01).
Clone formation rate of cells in each group
There was no statistic significance in clone formation
rate of cells of simple agent group (P > 0.05), compared
with that of control group. whereas there was a signifi-
cant difference between clone formation rate of simple
radiotherapy group and clone formation rate of com-
bined treatment group, compared with that of control
group, their relative clone formation rates were 51% and
26% respectively (See table 1).
Results of in vivo experiment
After experiments, tumor mass of each group was
weighed and tumor inhibition rates were calculated (see
table 2). Results of in vivo experiment showed there
were significant differences between the three treatment
groups and control group, which indicated combined
treatment group was superior to simple treatment
group.
Calculation of radiosensitization per tumor mass
E=( T 2/T1)×( T 3/T1)=0 . 3 8 ;0=( T 4/T1) = 0.12; E/0
= 3.17 (> 1.4). Above the results indicated the
radiosensitization of HSV-TK/GCV suicide gene system
was existing(E/O = 3.17 > 1.4).
Discussion and conclusion
Tumor gene-radiotherapy is a new thought put forward
in recent years to treat tumor. It transfers gene into the
body, which can kill tumor and enhance sensitivity of
radiation. It has synergism of radiation and gene in local
radiotherapy [2]. Recent research has shown that HSV-
TK can enhance sensitivity of radiation [10]. Many scho-
lar hold that radiotherapy can enhance effect of suicide
gene to inhibit tumor [11], and increase tumor cell
apoptosis and tumor immunity with HSV-TK gene [12].
On the other hand, suicide gene therapy is one of the
few gene treatment systems which may enhance radia-
tion sensitivity [13]. Acyclic uzarin, propoxy uzarin and
5-FC have effect to enhance sensitivity. Kim et al [14]
found that 9 L glioma transducted with HSV-TK gene
was more sensitive to rays after GCV treatment twice
24 h before and after radiation. Sensitizer enhancement
ratio (SER) is 1.6. Khil et al [15] transferred CD gene to
intestine cancer cells, radiated for 72 h, and exposed
them to 20 g/L 5-FC, then radiation sensitivity was
increased 2.38 times compared with cells without trans-
fected CD gene. In present study the author used HSV-
TK/GCV suicide gene therapy system, combined with
60Co radiation, to conduct in vitro and in vivo experi-
ments on human cervical cancer Hela. In in vitro the
inhibition rates of Hela cell proliferation in the gene
treatment group and radiotherapy group and combine
treatment group were 45.8%, 42.4% and 87.5% respec-
tively, compared with gene treatment group and radio-
therapy group, difference in combined treatment group
was significant (P < 0.01). The ratio of apoptosis among
the gene treatment group, radiotherapy group and com-
bined treatment group were (22.76 ± 3.51)%, (25.16 ±
3.17)%, (45.27 ± 5.15)% respectively compared with gene
treatment group and radiotherapy group, difference in
combined treatment group was significant (P < 0.01).
Moreover, In vivo nude mice cervical cancer model trea-
t e de x p e r i m e n ts h o w e dt h a tt h e r ew e r es i g n i f i c a n td i f -
ferences in the three treatment groups, compared with
control group; there was a significant difference in com-
bined treatment group(P < 0.01), compared with gene
treatment group or radiotherapy group, combined treat-
ment group was superior to simple treatment group,
which was in consistent with the study of NishiharaI
et al [16]. In addition, the authors observed the radio-
sensitization of HSV-TK/GCV suicide gene system in
the present study. Radiosensitization of HSV-TK/GCV
was tested by clone formation rate of cells. The dosage
of GCV was decided in 1/10 of effective concentration
(i.e. l μg/ml) according to preliminary experiment result
in order to remove proper cyto-toxic effect of GCV.
Figure 1 MTT experiments showed the inhibition rates of Hela/
TK cell growth induced by different methods and the
inhibition rates were 45.8 ± 7.3%, 42.4 ± 5.6% and 87.5 ±
10.32% respectively. Data were presented as the means ± SD of
each experiments performed in triplicate. **P < 0.01 (gene
treatment and
60Co radiotherapy group vs combined treatment
groups) according to Student’s t-test.
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60Co radiotherapy group; C. Combined treatment; D. control group, and the cells of apoptotic index (AI) were 22.76 ± 3.51%, 25.15 ± 3.17%,
45.27 ± 5.15, 0.42 ± 0.13% respectively.
Table 1 Clone formation rates and relative clone
formation rates of HeLa cells
(%)
Group formation rate (%) Clone formation
rate (%)
relative clone
Control(n = 3) 72 ± 11 -
Simple agent(n = 3) 69 ± 13 -
Simple radiotherapy (n = 3) 37 ± 6* 51 ± 11
#
Combined treatment(n = 3) 19 ± 4* 26 ± 7
Note: Compared with control group, * P < 0.01; compared with combined
treatment group, # P < 0.01.
Table 2 Inhibition of transplanted subcutaneous tumor of
mice (%)
Group tumor
weight (g)
tumor inhibition
rate (%)
Control(n = 10) 2.22 ± 0.28 -
Radiotherapy(n = 10) 1.43 ± 0.05* 35.8 ± 4.9
▫
Gene treatment(n = 10) 1.34 ± 0.14* 39.5 ± 4.0
▫
Combined treatment(n = 10) 0.28 ± 0.04* 87.9 ± 2.1
Note: Compared with control group, * P < 0.01; compared with combined
treatment group,
▫ P<0 . 0 1 .
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in clone formation rate of cells of simple agent group (P
> 0.05), compared with that of control group, it meant
that cyto-toxic effect of GCV was excluded. Whereas
there was a significant difference between clone forma-
tion rate of simple radiotherapy group and clone forma-
tion rate of combined treatment group, compared with
that of control group, their relative clone formation
rates were 51% and 26% respectively (See table 1). It
meant that combined treatment group was more sensi-
tive to rays. Above the results indicated the radiosensiti-
zation of HSV-TK/GCV suicide gene system was
existing(E/O = 3.17 > 1.4). Which was in consistent
with the study of NishiharaI et al [16]. In short, in this
present study in vitro and in vivo experiments showed
HSV-TK/GCV system and
60Co may have synergism,
when GCV less than effective dose was used in com-
bined
60Co radiotherapy, sensitivity of HSV-TK gene to
rays was enhanced significantly.
With regard to mechanism of the radiosensitization of
HSV-TK/GCV suicide gene system, it was believed that
when GCV enters cells transfected by HSV-TK gene, it
converts into GCV-triphosphate, which can inhibit
tumor cell repair of potentially lethal damage (PLD) and
mix in DNA as competitive inhibitor of dTTP to
enhance radiation sensitivity, reduce dose and toxic
effect and improve therapeutic effect [17]. At present,
t h ea p p r o a c ho fH S V - T K / G C Vs u i c i d eg e n es y s t e m
combined radiotherapy on tumor therapy has not yet
been used on clinical stage. But the investigation about
wild type p53 gene inducing malignant cell apoptosis
and its sensitization has been used on clinical stage.
Swisher et al [18] had reported clinical stage II trial
results about rAd2 p53 combined radiotherapy on non-
small-cell lung cancer. The results showed: among the
19 patients, tumor cell has not yet been found by patho-
biopsy in 63% (12/19). But tumor focus could be found
in 16% (3/19) subjects accepting gene therapy, and the
effective rate was less than 20% in subjects accepting
radiotherapy. Those illustrated there were induction of
p53 regulated genes and tumor regression in lung can-
cer patients after intratumoral delivery of adenoviral p53
(INGN 201) and radiation therapy.
On the whole, there were intimate relation between
HSV-TK gene and tumor radiosensitivity. With mole-
cule radiobiological development, it will be more clear
that HSV-TK can enhance sensitivity of radiation and
radiotherapy can enhance effect of suicide gene to inhi-
bit tumor, which will give malignant tumor treatment
more new approach and expectation; Meanwhile it will
be very important to formulate correct combined thera-
peutic regimen and to predict curative effect and to
appraise prognosis.
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